Different regulatory pathways are involved in the proliferative inhibition of two types of leukemia cell lines induced by paclitaxel.


Paclitaxel, one of the broadest-spectrum anticancer agents, is currently being used in the treatment of patients with solid tumors. In the present study, we compared the effect of paclitaxel on two types of leukemia cells. Our results showed that paclitaxel could inhibit the proliferation of MEL and K562 cells in a dose- and time-dependent manner. The… (More)
DOI: 10.3892/or.2013.2624


7 Figures and Tables

Slides referencing similar topics